Table 1. Obstetric and gynecological uses of mifepristone.
FDA: Food and Drug Administration; LNG: levonorgestrel; DMPA: depot medroxyprogesterone acetate; LH: luteinizing hormone; IVF: in vitro fertilization
Obstetric and gynecological uses | Indications | Recommended doses |
FDA-approved use | ||
1 | Early pregnancy termination | Mifepristone 200 mg orally on day 1, misoprostol 800 µg buccally after 24-48 hours |
Proposed uses | ||
1 | Second-trimester termination of pregnancy | Mifepristone 200 mg orally, followed by misoprostol 200 μg vaginally 3 hourly [15] |
2 | Missed abortion and fetal demise | 600 mg/day for 2 days [19]; 200 mg orally with misoprostol (14-28 weeks of gestation) [20] |
3 | Menstrual induction | Mifepristone 600 mg single dose [22]; mifepristone 150 mg, misoprostol 0.4 mg vaginally after 2 days [24] |
4 | Emergency contraception | Less than 25 mg single dose [29]; 25-50 mg single dose [29] |
5 | Estrogen-free contraceptive pill | 2 and 5 mg daily [30]; 25 mg once weekly [36]; 200 mg once a month on the 16th day of the menstrual cycle [35] |
6 | Cervical dilatation | 600 mg orally single dose [39] |
7 | Induction of labor | 200 mg single dose [42] |
8 | Ectopic pregnancy | Methotrexate 50 mg/m2 intramuscularly and mifepristone 600 mg orally [44,45] |
9 | Endometriosis | 50 and 100 mg daily for 6 months [46]; 50 mg for 6 months [47] |
10 | Leiomyomas | 10-25 mg daily for 3 months [55] |
11 | Adenomyosis | 5 mg daily [60] |
12 | Breakthrough bleeding in LNG and DMPA | 50 mg every 2 weeks for 24 weeks [61]; 100 mg every 30 days for 3 months [63] |
13 | Premature LH surges undergoing controlled ovarian hyperstimulation in IVF | 2.5 mg two doses after follicle aspiration [66]; 40 mg daily [67] |